Asia Pacific Hemostasis Diagnostics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 2,000.00$ 6,900.00

Asia Pacific Hemostasis Diagnostics Market: By Product Type (Systems, Consumables, Point-of-Care Testing Devices), By Test Type (Fibrinogen Test, Activated Clotting Time, Platelet Function, Prothrombin Time, Heparin & Protamine Dose-Response Test For ACT, Activated Partial Thromboplastin Time, Anti-Factor Xa, Other Coagulation Tests), By Technology (Optical, Mechanical, Electrochemical, and Others), By End-User (Hospitals, Clinics, Diagnostic Laboratories, Others (POC)), and Country

 

 


 

$ PRICE - $ 2,000.00$ 6,900.00
Region Asia Pacific
Clear selection
Clear
$ PRICE - $ 2,000.00$ 6,900.00
FacebookTwitterLinkedinEmail

Report

Description

Asia Pacific hemostasis diagnostics market size is valued at USD 748.2 million in 2021 and is expected to grow at a CAGR of 10.2% during the forecast period 2022 to 2028. The global market provides a detailed overview of the Asia Pacific hemostasis diagnostics market, and that can be segmented by product type, by test type, by technology, and by end user. By product type, the market has been segmented into Systems, Consumables, Point-of-Care Testing Devices. Point-of-Care Testing Devices segment is likely to be the largest and fastest-growing segment in terms of type. Based on test type, the Asia Pacific hemostasis diagnostics market is segmented into Fibrinogen Test, Activated Clotting Time, Platelet Function, Prothrombin Time, Heparin & Protamine Dose-Response Test For ACT, Activated Partial Thromboplastin Time, Anti-Factor Xa, Other Coagulation Tests. Among these, the Fibrinogen Test segment is growing at a significant rate in the global hemostasis diagnostic market during the forecast period 2022-2028. Based on technology, the Asia Pacific hemostasis diagnostics market is segmented into Optical, Mechanical, Electrochemical, and Others. The optical segment accounts for the largest share in 2021.Based on end user, the segment has been segregated into Hospitals, Clinics, Diagnostic Laboratories, Others (POC). The hospital segment is expected to dominate other segments in the market during the forecast period according to precision business insights. Hemostasis diagnostics devices helps in detection of hemostatic abnormalities such as excessive bleeding. Hemostasis is a body’s normal reaction to an injury to reduce blood loss and repair on the injury. The rise in the prevalence of several diseases such as cancer, diabetes, etc, population and lifestyles changes, the rise in the prevalence of hemophilia, and the increase in technological advancements are the major drivers in the Asia Pacific hemostasis market. Furthermore, increased awareness of hemostasis is also expected to boost the Asia Pacific diagnostics market.

 

Key Developments:

In July 2020, Sysmex Corporation launched new products in the hemostasis field, the Automated Blood Coagulation Analyzers CN-6500/CN-3500.

Asia Pacific Hemostasis Diagnostics Market

MARKET SUMMARY
-
10.2% CAGR
  • Study Period– 2022-2028
  • Base Year– 2021
  • CAGR–10.2%

Asia Pacific Hemostasis Diagnostics Market

  • The asia pacific hemostasis diagnostics market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • The asia pacific hemostasis diagnostics market is segmented based on product type, test type, technology, end user and by country
Key Players
  • Hoffmann-La Roche Ltd.
  • Sysmex Corporation
  • Abbott Laboratories
  • Alere Inc.
  • Nihon Kohden Corporation
Asia Pacific Hemostasis Diagnostics Market Drivers

Growing geriatric population, rise in prevalence of various diseases such as hemophilia are anticipated to propel the market growth over the forecast years. Moreover, the increasing technological advancement is also boosting the Asia Pacific market growth over the forecast years.


Japan got Significant Share

Asia Pacific Hemostasis Diagnostics Market

China is expected to witness a significant growth rate during the forecast period it holds a tremendous potential market for Asia Pacific diagnostics due to increasing geriatric population, rising cardiovascular diseases.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The report provides granular level information about the market size, regional market share, and forecast
  • The report covers in-detail insights about the competitor’s overview, key findings, and their key strategies
  • The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
  • The report tracks recent innovations, key developments and start-up’s details that are working in the industry
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
Asia Pacific Hemostasis Diagnostics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The fastest-growing segment of the Asia Pacific hemostasis diagnostics market is point of care testing devices because of minimally trained professionals can also effectively use POC instruments for diagnosis.

 

 

 

 

The growing technological advances in molecular diagnostics, immunoassays, inexpensive diagnostic products, monoclonal antibodies, laboratory automation is the key trends in the Asia Pacific hemostasis diagnostic market.

The growing geriatric population is driving the number of surgeries such as cardiovascular diseases (CVD), using hemostasis devices which can be the major opportunity in the global hemostasis diagnostic market.

Rising prevalence of hemophilia and growing geriatric populations are the major driver in the global hemostasis diagnostic market. However, the lack of awareness about hemostasis diseases in emerging countries may hamper the market growth in the Asia Pacific region.


Report

Table Of Content


Report

Company Profile

  • Hoffmann-La Roche Ltd.
  • Sysmex Corporation
  • Abbott Laboratories
  • Alere Inc.
  • Nihon Kohden Corporation
  • Siemens Healthineers
  • Danaher Corporation
  • Instrumentation Laboratory
  • Grifols S.A
  • Beckman Coulter

Description

Asia Pacific hemostasis diagnostics market size is valued at USD 748.2 million in 2021 and is expected to grow at a CAGR of 10.2% during the forecast period 2022 to 2028. The global market provides a detailed overview of the Asia Pacific hemostasis diagnostics market, and that can be segmented by product type, by test type, by technology, and by end user. By product type, the market has been segmented into Systems, Consumables, Point-of-Care Testing Devices. Point-of-Care Testing Devices segment is likely to be the largest and fastest-growing segment in terms of type. Based on test type, the Asia Pacific hemostasis diagnostics market is segmented into Fibrinogen Test, Activated Clotting Time, Platelet Function, Prothrombin Time, Heparin & Protamine Dose-Response Test For ACT, Activated Partial Thromboplastin Time, Anti-Factor Xa, Other Coagulation Tests. Among these, the Fibrinogen Test segment is growing at a significant rate in the global hemostasis diagnostic market during the forecast period 2022-2028. Based on technology, the Asia Pacific hemostasis diagnostics market is segmented into Optical, Mechanical, Electrochemical, and Others. The optical segment accounts for the largest share in 2021.Based on end user, the segment has been segregated into Hospitals, Clinics, Diagnostic Laboratories, Others (POC). The hospital segment is expected to dominate other segments in the market during the forecast period according to precision business insights. Hemostasis diagnostics devices helps in detection of hemostatic abnormalities such as excessive bleeding. Hemostasis is a body’s normal reaction to an injury to reduce blood loss and repair on the injury. The rise in the prevalence of several diseases such as cancer, diabetes, etc, population and lifestyles changes, the rise in the prevalence of hemophilia, and the increase in technological advancements are the major drivers in the Asia Pacific hemostasis market. Furthermore, increased awareness of hemostasis is also expected to boost the Asia Pacific diagnostics market.

 

Key Developments:

In July 2020, Sysmex Corporation launched new products in the hemostasis field, the Automated Blood Coagulation Analyzers CN-6500/CN-3500.

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX